According to our (Global Info Research) latest study, the global Anlotinib Hydrochloride market size was valued at US$ 568 million in 2025 and is forecast to a readjusted size of US$ 1206 million by 2032 with a CAGR of 9.2% during review period.
In 2025, global production of Anlotinib Hydrochloride reached approximately 12.5 million units.Anlotinib Hydrochloride is an oral small-molecule multi-target tyrosine kinase inhibitor (TKI) primarily used for the treatment of various solid tumors, including non-small cell lung cancer, soft tissue sarcoma, and thyroid cancer. It exerts its effects by simultaneously inhibiting multiple signaling pathways, such as vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and platelet-derived growth factor receptors (PDGFR), thereby achieving anti-angiogenic activity and suppression of tumor growth. Anlotinib hydrochloride offers the convenience of oral administration, multi-target synergistic effects, and a certain degree of broad-spectrum antitumor activity, making it clinically valuable in the treatment of advanced cancers as well as in maintenance therapy.
Anlotinib Hydrochloride, as a multi-target tyrosine kinase inhibitor (TKI), holds an important position in China’s oncology targeted therapy market, particularly demonstrating strong competitiveness in indications such as non-small cell lung cancer and soft tissue sarcoma. With the continuous rise in cancer incidence and the increasing adoption of precision medicine, the market for small-molecule targeted therapies is steadily expanding, providing a stable demand foundation for this drug. From a competitive landscape perspective, multi-target TKIs represented by Sorafenib and Lenvatinib, along with emerging therapies such as immune checkpoint inhibitors, constitute the primary competitive environment. However, anlotinib hydrochloride, with its multi-target mechanism, broad indication coverage, and domestic pricing advantages, demonstrates differentiated competitiveness in later-line and maintenance therapy settings. On the policy side, its inclusion in the national reimbursement drug list helps improve patient accessibility and promote market expansion, although volume-based procurement and healthcare cost-control policies continue to exert downward pressure on pricing. From a competitive standpoint, the increasing availability of similar targeted therapies from both domestic and international players, combined with the rise of immunotherapy-based combination regimens, is intensifying market competition. Therefore, the future market performance of anlotinib hydrochloride will depend on its progress in combination strategies, expansion into additional indications (such as other solid tumors), and the accumulation of real-world evidence, as well as its overall competitive balance in efficacy, safety, and cost.
This report is a detailed and comprehensive analysis for global Anlotinib Hydrochloride market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Anlotinib Hydrochloride market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Anlotinib Hydrochloride market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Anlotinib Hydrochloride market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Anlotinib Hydrochloride market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Anlotinib Hydrochloride
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Anlotinib Hydrochloride market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Chia Tai Tianqing Pharmaceutical Group, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Anlotinib Hydrochloride market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
8 mg/capsule
12 mg/capsule
Market segment by Dosage Form
Capsule
Tablet
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Application
Non-small Cell Lung Cancer(NSCLC)
Small Cell Lung Cancer(SCLC)
Soft Tissue Sarcoma(STS)
Thyroid Cancer
Hepatocellular Carcinoma(HCC)
Others
Major players covered
Chia Tai Tianqing Pharmaceutical Group
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Anlotinib Hydrochloride product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Anlotinib Hydrochloride, with price, sales quantity, revenue, and global market share of Anlotinib Hydrochloride from 2021 to 2026.
Chapter 3, the Anlotinib Hydrochloride competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Anlotinib Hydrochloride breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Anlotinib Hydrochloride market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Anlotinib Hydrochloride.
Chapter 14 and 15, to describe Anlotinib Hydrochloride sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Anlotinib Hydrochloride. Industry analysis & Market Report on Anlotinib Hydrochloride is a syndicated market report, published as Global Anlotinib Hydrochloride Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Anlotinib Hydrochloride market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.